| Editorial board: Núria Guañabens (Barcelona, Spain) | Editor in chief
Carmen Huesa (Paisley, UK), Athanasios Anastasilakis (Thessaloniki, Greece), Marco Ponzetti (L'Aquila, Italy) | Co-editors |
|
|
|
|
|
|
|
|
| ECTS Annual Meeting, Salzburg 13-16 May 2017 |
|
|
|
|
| Curtains up for ECTS 2017!
by Claus-C. Glüer
Hello, out there! No more mailing, skyping, whatsappchatting its time for the real splash! Cant wait to head for Salzburg for our annual gathering and hear first hand about the latest exciting developments in our field. The unique recipe of ECTS Annual Congress: Combine great topics with fabulous speakers, highest standards in a stimulating and enjoyable atmosphere. For details on the fascinating programme...
|
Quick links
Upcoming activities |
|
| ECTS 2017 All you need to know to better plan your congress experience
By Roberta Mugnai
With ECTS 2017 about to start, its the perfect time to organise your agendas! The Congress is also a great opportunity to meet colleagues and friends, set up new collaborations and ... exercise! This year for the first time, ECTS is hosting a fundraising relay race.
In this issue, we have brought together some of the practical information you will need for the Congress and present you some important activities that will take pace on-site, such as opening ceremony, awards, ECTS General Assembly. The ECTS Congress Team has also prepared a few more surprises to maximise your delegate experience. Join us in Salzburg in a few days and enjoy a programme rich of science, collaboration and exchange! We cant wait you to meet you there!
|
ECTS Academy: Get involved! |
|
| Reasons to attend the ECTS meeting. From the perspective of an academic clinician
By Erik Fink Eriksen
As a academic clinician I enjoy participating in ECTS. The congress has increased its focus on clinical updates and also tries to nurture links between the different subspecialities. Calcium metabolism and osteoporosis research has become extremely complex with linking calcium homeostasis and bone remodeling to metabolism, the central nervous system, vascular research etc. ECTS makes sure to have sessions dealing with these aspects. Furthermore being interested in translational aspects of clinical research the interactions with basic research has become very productive and fruitful at ECTS. You always come home with new ideas
|
The ECTS Academy has be founded as a daughter society of the ECTS. The concept follows the model of interdisciplinary Young Academies: young researchers self-organise their society to foster personal contact and networking among the most talented young scientists.
Are you interested to participate in the ECTS Academy as New Investigator, Advisor or Affiliated Society? Check here how you can get involved! |
|
| Join ECTS today! Access all of our exclusive grants, training courses, reduced meeting fees and much more!
|
|
| ECTS 2017: check out the highlights! |
|
|
| ECTS 2017 Relay Race, run for a good cause! |
|
|
| Register for the next ECTS live webinar |
|
|
|
|
|
FDA approves Abaloparatide
Abaloparatide is a bone-anabolic, PTHrP-derived drug that could help solve many of the problems associated with bisphosphonates treatment in osteoporosis. A subcutaneous formulation for this drug (TYMLOS(TM) by Radius health) has been recently approved by FDA, after more than 5 years since the last osteoporosis drug was approved. The ACTIVExtend clinical trial showed a significant reduction of both vertebral and non-vertebral fractures in most patients, regardless of antrophometric variables. The obvious advantage of this drug is its bone-anabolic effect, that stimulates osteoblastic bone deposition, as opposed to the bone-freezing effect bisphosphonates have, that may cause severe adverse effects (osteonecrosis of the jaw, osteomielites and atypical fractures). The just-as-obvious disadvantage will be the price of the biotechnological drug, that may stop many healthcare systems from adopting it, while the long-term increase in osteosarcoma incidence still poses a serious threat...
|
|
| Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG
Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position statement of several interdisciplinary cancer and bone societies involved in the management of AI-associated bone loss (AIBL).
|
|
|
|
| ECTS is thankful to its Corporate Members and other companies that have supported ECTS activities through unrestricted educational grants. These sponsors have in no way contributed to or influenced the content. |
|
|
